VCYT Veracyte Corp: Market Capitalization to Book Value Ratio

Veracyte, Inc. (VCYT) leverages advanced AI algorithms and unique RNA signatures to help clinics avoid unnecessary surgical interventions. The business is protected by years of clinical validation and patents, which make it impossible to replicate its medical database. The current metric stands at 2.82. The stock's price chart demonstrates scaling potential through a laboratory network, which significantly reduces the cost per individual analysis.

Veracyte, Inc. (VCYT) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

VCYT (Veracyte Inc): analytical breakdowns and indicator data

- price and consensus price forecast:

Stock Quotes Veracyte, Inc.|VCYT - Analyst Forecast Prices

- market capitalization data:

Market Capitalization Veracyte Corp|VCYT - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share Veracyte|VCYT - Book Capitalization|Market Value to Book Value Ratio veracyte.com|VCYT - Total Business Assets

- debt and liquidity data:

Total Debt to Capital Veracyte, Inc.|VCYT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Veracyte Corp|VCYT - Company Cumulative Debt|Debt to Book Capitalization Ratio Veracyte Corp

Fundamental valuation:VCYT (Veracyte, Inc.)

The protection of the Veracyte, Inc. (VCYT) genomic platform through patents and insurance coverage is reflected in the price-to-book ratio dynamics. This indicator compares the current market share price with the company's net assets, allowing investors to assess the premium paid for intellectual capital and determine the fair value of the business relative to average US market industry thresholds.

Main competitors